ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis
OSL:AZT - NO0010014632 - Common Stock
29.4 NOK
+0.6 (+2.08%)
Taking everything into account, AZT scores 5 out of 10 in our fundamental rating. AZT was compared to 73 industry peers in the Biotechnology industry. Both the profitability and the financial health of AZT get a neutral evaluation. Nothing too spectacular is happening here. AZT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZT was profitable.
In the past year AZT had a positive cash flow from operations.
AZT had positive earnings in each of the past 5 years.
In the past 5 years AZT always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 0.64%, AZT is doing good in the industry, outperforming 72.46% of the companies in the same industry.
With a decent Return On Equity value of 0.68%, AZT is doing good in the industry, outperforming 76.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.64% | ||
| ROE | 0.68% | ||
| ROIC | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 2.25%, AZT is in the better half of the industry, outperforming 78.26% of the companies in the same industry.
In the last couple of years the Profit Margin of AZT has declined.
AZT's Gross Margin of 94.33% is amongst the best of the industry. AZT outperforms 92.75% of its industry peers.
In the last couple of years the Gross Margin of AZT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.25% | ||
| GM | 94.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
2. Health
2.1 Basic Checks
AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZT has been increased compared to 1 year ago.
The number of shares outstanding for AZT has been increased compared to 5 years ago.
The debt/assets ratio for AZT has been reduced compared to a year ago.
2.2 Solvency
AZT has an Altman-Z score of 44.02. This indicates that AZT is financially healthy and has little risk of bankruptcy at the moment.
AZT's Altman-Z score of 44.02 is amongst the best of the industry. AZT outperforms 98.55% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that AZT is not too dependend on debt financing.
AZT has a better Debt to Equity ratio (0.02) than 75.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 44.02 |
ROIC/WACCN/A
WACC8.48%
2.3 Liquidity
A Current Ratio of 17.49 indicates that AZT has no problem at all paying its short term obligations.
AZT has a Current ratio of 17.49. This is amongst the best in the industry. AZT outperforms 97.10% of its industry peers.
AZT has a Quick Ratio of 16.53. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 16.53, AZT belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.49 | ||
| Quick Ratio | 16.53 |
3. Growth
3.1 Past
AZT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.89%.
Measured over the past years, AZT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -43.42% on average per year.
The Revenue for AZT has decreased by -12.26% in the past year. This is quite bad
The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)-88.89%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%0.96%
3.2 Future
The Earnings Per Share is expected to grow by 69.92% on average over the next years. This is a very strong growth
Based on estimates for the next years, AZT will show a quite strong growth in Revenue. The Revenue will grow by 18.97% on average per year.
EPS Next Y-2.61%
EPS Next 2Y68.81%
EPS Next 3Y69.92%
EPS Next 5YN/A
Revenue Next Year8.45%
Revenue Next 2Y14.86%
Revenue Next 3Y16.18%
Revenue Next 5Y18.97%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
AZT is valuated quite expensively with a Price/Earnings ratio of 980.00.
Compared to the rest of the industry, the Price/Earnings ratio of AZT indicates a somewhat cheap valuation: AZT is cheaper than 76.81% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.24, AZT is valued quite expensively.
With a Price/Forward Earnings ratio of 73.69, AZT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AZT indicates a somewhat cheap valuation: AZT is cheaper than 79.71% of the companies listed in the same industry.
AZT is valuated expensively when we compare the Price/Forward Earnings ratio to 22.81, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 980 | ||
| Fwd PE | 73.69 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AZT's earnings are expected to grow with 69.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.81%
EPS Next 3Y69.92%
5. Dividend
5.1 Amount
No dividends for AZT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:AZT (8/22/2025, 7:00:00 PM)
29.4
+0.6 (+2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.83%
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner ChangeN/A
Market Cap1.50B
Analysts76.67
Price Target28.56 (-2.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)509.19%
Min EPS beat(2)-269.73%
Max EPS beat(2)1288.12%
EPS beat(4)1
Avg EPS beat(4)208.45%
Min EPS beat(4)-269.73%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)114.16%
EPS beat(12)3
Avg EPS beat(12)63.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-13.1%
Max Revenue beat(2)2.64%
Revenue beat(4)1
Avg Revenue beat(4)-10.13%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)2
Avg Revenue beat(8)-7.15%
Revenue beat(12)2
Avg Revenue beat(12)-7.23%
Revenue beat(16)5
Avg Revenue beat(16)-4.68%
PT rev (1m)47.37%
PT rev (3m)47.37%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)-22.86%
EPS NY rev (3m)-22.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 980 | ||
| Fwd PE | 73.69 | ||
| P/S | 15.38 | ||
| P/FCF | N/A | ||
| P/OCF | 280.23 | ||
| P/B | 4.66 | ||
| P/tB | 5.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.03
EY0.1%
EPS(NY)0.4
Fwd EY1.36%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.1
OCFY0.36%
SpS1.91
BVpS6.31
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.64% | ||
| ROE | 0.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.25% | ||
| GM | 94.33% | ||
| FCFM | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 80.55% | ||
| Cap/Sales | 6.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.49 | ||
| Quick Ratio | 16.53 | ||
| Altman-Z | 44.02 |
F-Score5
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.89%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-2.61%
EPS Next 2Y68.81%
EPS Next 3Y69.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%0.96%
Revenue Next Year8.45%
Revenue Next 2Y14.86%
Revenue Next 3Y16.18%
Revenue Next 5Y18.97%
EBIT growth 1Y-168.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year342.86%
EBIT Next 3Y124.31%
EBIT Next 5YN/A
FCF growth 1Y-102.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.71%
OCF growth 3Y-71.92%
OCF growth 5Y-16%